myo-Inositol
|
Basic information |
| Metabolite name | myo-Inositol |
 | HMDB0000211 |
 |
C00137 |
 |
892 |
| Synonyms | Inositol myo-; |
| No. of studies | 79 |
|
Basic information |
| Metabolite name | myo-Inositol |
| HMDB0000211 |
|
C00137 |
|
892 |
| Synonyms | Inositol myo-; |
| No. of studies | 79 |
|
Relationship between myo-Inositol and depression (count: 79) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M001 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M021 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M025 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M040 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M044 | Type2 | CUMS + rTMS group vs. CUMS + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M045 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M047 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M047 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M047 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M047 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M053 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M053 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Down |
| Study M066 | Type1 | CUMS vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M071 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Down |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M085 | Type3 | ketamine group vs. control group at 24 h after treatment | Serum | Cynomolgus monkey | Down |
| Study M086 | Type5 | paroxetine-treated responder group vs. non-responder group | Hippocampus | DBA/2J mouse | Up |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Down |
| Study M100 | Type1 | CS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M1058 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M1058 | Type1 | depression group vs. control group | Basal ganglia | Human | Down |
| Study M1058 | Type1 | depression group vs. control group | Ventral prefrontal white matter | Human | Down |
| Study M1058 | Type1 | depression group vs. control group | Dorsal thalamus | Human | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1099 | Type1 | chronic social isolation group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M113 | Type2 | CUMS + exercise group vs. CUMS group | Serum | Wistar rat | Up |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Up |
| Study M119 | Type1 | LH group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | CRS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Down |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M243 | Type1 | depression group vs. control group | Dorsolateral prefrontal cortex | Human | Up |
| Study M255 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Up |
| Study M262 | Type1 | stress group vs. control group | Brain | Tree shrew | Down |
| Study M269 | Type1 | first episode depression group vs. control for first episode group | Hippocampus | Human | Up |
| Study M271 | Type1 | depression group vs. control group | Hypothalamus | Human | Down |
| Study M271 | Type1 | depression group vs. control group | Thalamus | Human | Down |
| Study M277 | Type3 | FST + DMI group vs. FST group | Hippocampus | C57BL/6 mouse | Down |
| Study M277 | Type3 | FST + DMI group vs. FST group | Dorsolateral prefrontal cortex | C57BL/6 mouse | Down |
| Study M285 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M310 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M327 | Type1 | depression group vs. control group | Parietal cortex | Human | Down |
| Study M347 | Type1 | depression group vs. control group | Thalamus | Human | Down |
| Study M347 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M350 | Type1 | depression group vs. control group | Hippocampus | Human | Down |
| Study M350 | Type1 | depression group vs. control group | Amygdala | Human | Down |
| Study M350 | Type1 | depression group vs. control group | Medial prefrontal cortex | Human | Down |
| Study M355 | Type2 | stress + clomipramine group vs. stress group | Brain | Tree shrew | Up |
| Study M355 | Type2 | stress + L-760,735 group vs. stress group | Brain | Tree shrew | Up |
| Study M360 | Type1 | depression group vs. control group | Posterior cingulate cortex | Human | Up |
| Study M461 | Type1 | LD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M472 | Type3 | S-Ket group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | (2S,6S)-HNK group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | R-Ket group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Up |
| Study M473 | Type1 | high-fat diet group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M473 | Type1 | high-fat diet group vs. control group | Striatum | C57BL/6J mouse | Up |
| Study M478 | Type3 | ketamine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hippocampus | Wistar rat | Up |
| Study M486 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M491 | Type1 | post-CFSS vs. pre-CFSS | Prefrontal cortex | Wistar rat | Up |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Up |
| Study M492 | Type2 | ACTH + CGA group vs. ACTH group | Urine | Wistar rat | Up |
| Study M519 | Type1 | susceptible group vs. control group | Dorsal striatum | C57BL/6N mouse | Up |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M547 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M564 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M569 | Type2 | LPS + HPF group vs. LPS group | Serum | ICR mouse | Down |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M598 | Type1 | MS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M611 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Kidney | Sprague-Dawley rat | Unknown |
| Study M619 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M619 | Type2 | CUMS + middle dose of Jiaotaiwan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M619 | Type2 | CUMS + low dose of Jiaotaiwan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M685 | Type1 | SDS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Up |
| Study M738 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M738 | Type1 | CMS + Xiaoyaosan group vs. CMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M775 | Type1 | prenatal stress group vs. control group | Brain | Swiss Webster mouse | Up |
| Study M799 | Type1 | MDD group vs. control group | Middle temporal visual area | Human | Down |
| Study M867 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M935 | Type2 | chronic social isolation + tianeptine group vs. chronic social isolation group | Hippocampus | Wistar rat | Down |
| Study M935 | Type4 | chronic social isolation + tianeptine group vs. chronic social isolation + tianeptine resilient group | Hippocampus | Wistar rat | Down |
| Study M935 | Type4 | chronic social isolation + tianeptine group vs. chronic social isolation + tianeptine resilient group | Serum | Wistar rat | Up |
| Study M943 | Type1 | CUMS group vs. control group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + high dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | ICR mouse | Down |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |